A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: Results of a European phase II study

Cytotherapy

Volumn 11, Issue 8, 2009, Pages 992-1001

  Fruehauf, Stefan ^a,b   Veldwijk, Marlon Romano ^a   Seeger, Timon ^a   Schubert, Mario ^a   Laufs, Stephanie ^c   Topaly, Julian ^a   Wuchter, Patrick ^a   Dillmann, Falk ^a   Eckstein, Volker ^a   Wenz, Frederik ^a   Goldschmidt, Hartmut ^a   Ho, Anthony Dick ^a   Calandra, Gary ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Paracelsus Klinik   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d GENZYME CORPORATION   (United States)

Author keywords

AMD3100; Granulocyte colony stimulating factor; Mobilization; Peripheral blood progenitor cells.

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

EID: 70350757228     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903121245     Document Type: Article

References (40)

1. Gratwohl A, Baldomero H , Passweg J , Frassoni F , Niederwieser D, Schmitz N , et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003; 17: 941-959 (Pubitemid 36626323)
2. Peled A, P etit I, Kollet O , Magid M , Ponomaryov T , Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR. Science 1999; 283: 845-848
3. Fruehauf S , Srbic K, Seggewiss R , Topaly J , Ho AD. Functional characterization of podia formation in normal and malignanThematopoietic cells. J Leuk Biol 2002; 71: 425 - 32.
4. Nie Y H an YC, Z ou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008; 205: 777-783
5. Foudi A , J arrier P, Z hang Y , W ittner M , Geay JF, Lecluse Y, e t al. Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood 2006; 107: 2243-2251
6. Dabusti M , Lanza F, C ampioni D , Castagnari B , Tieghi A, Moretti S , et al. CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies. J Hematother Stem Cell Res 2003; 12: 425-434
7. Liles WC , Broxmeyer H E, Rodger E , Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 ; 102: 2728-2730
8. Broxmeyer H E, Orschell C M, C lapp D W , H angoc G , Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318
9. Larochelle A , Krouse A, M etzger M , Orlic D , Donahue R E, Fricker S, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006 ; 107: 3772-3778
10. Zeng Z , S hi Y X, S amudio I J, Wang R Y, L ing X , F rolova O , et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113:6215-6224
11. Liles WC, R odger E , Broxmeyer H E , Dehner C , B adel K , Calandra G , et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by singledose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300.
12. Flomenberg N , D evine SM , D ipersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106 : 1867-1874
13. Dipersio J F, Stadtmauer E A, N ademanee A , M icallef I N , Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-5726
14. Fruehauf S , S eeger T , M aier P , L i L , W einhardt S , L aufs S , et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSFprimed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006; 34: 1052-1059
15. Alsayed Y , N go H , R unnels J , L eleu X , Singha U K , Pitsillides C M , et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)- dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717
16. Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant. 2009 Jul 13. [Epub ahead of print]
17. Larochelle A , V ormoor J , H anenberg H, W ang JC , Bhatia M , Lapidot T, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nature Med 1996 ; 2 : 1329-1337
18. Terstappen LW, H uang S , S afford M , L ansdorp P M, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+ CD38+ progenitor cells. Blood 1991; 77; 1218-1227
19. Sutherland D R, Anderson L , K eeney M , Nayar R , C hin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flowcytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226
20. Fruehauf S , H aas R , Conradt C , M urea S , Witt B , Mohle R, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995; 85: 1219-1231
21. Keeney M , B rown W , G ratama J , P apa S , L anza F , Sutherland DR. Single platform enumeration of viable CD34(pos) cells. J Biol Regul Homeost Agents 2003 ; 17: 247-253
22. Punzel M , Liu D , Zhang T, Eckstein V , Miesala K , Ho AD. The symmetry of initial divisions of human hematopoietic progenitors is altered only by the cellular microenvironment. Exp Hematol 2003; 31 : 339-347
23. Klaus J, Herrmann D , Breitkreutz I , Hegenbart U , Mazitschek U , Egerer G, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2006 ; 78: 21-28
24. Kerre T C, De Smet G, De Smedt M , O ffner F , De Bosscher J , Plum J, et al. Both CD34+ 38+ and CD34+ 38- cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol 2001; 167 : 3692-3698
25. Bellucci R , D e Propris M S, B uccisano F, Lisci A , L eone G , Tabilio A, et al. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999; 23: 1-8.
26. Mohle R , P forsich M , F ruehauf S , W itt B , K ramer A. H aas R. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profi le compared with use dur ing steady-state hematopoiesis. Bone Marrow Transplant 1994 : 14: 827-832
27. Craig W , K ay R, C utler RL , Lansdorp P M. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993; 177 : 1331-1342
28. Yin A H , Miraglia S, Zanjani ED, Almeida-Porada G , Ogawa M , Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012
29. Oelschlaegel U, Bornhauser. M, Boxberger S , Kroschinsky F , Illmer T , Hoelig K, et al. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007 ;86 : 569-573
30. Schols D, Este JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR. Antiviral Res 1997 ; 35: 147-156
31. Aiuti A , T avian M , C ipponi A , F icara F , Zappone E , H oxie J , et al. Expression of CXCR4, the receptor for stromal cell-derived factor- 1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol 1999; 29: 1823-1831
32. Kahn J , B yk T, J ansson-Sjostrand L , Petit I, Shivtiel S, Nagler A , et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004 ; 103: 2942-2949
33. Bonig H , Priestley G V, Papayannopoulou T. Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood 2006 ; 107: 79-86.
34. Sutherland H J, E aves C J, L ansdorp PM, Thacker J D , Hogge DE. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78 : 666-672
35. Thess DA, Bonde J, Craft TP, Wirthlin L, Hohm S , Lahey R, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007 ; 13: 398-411.
36. Haas R , Witt B , M ohle R , G oldschmidt H , H ohaus S , Fruehauf S, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761
37. Devine SM , Vij R, Rettig M, Todt L, McGlauchlen K , Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998
38. Thenon P , S ovalat H , Bourderont D , O jeda-Uribe M , Arkam Y , Wunder E, et al. Role of the CD34+ 38+ cells in posttransplanThematopoietic recovery. Stem Cells 1998; 16( Suppl. 1): 113-122
39. Fruehauf S , Schmitt K, V eldwijk MR , Topaly J , Benner A , Zeller WJ, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colonystimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105: 786-794
40. Duhrsen U , Villeval JL, B oyd J , Kannourakis G , M orstyn G , Metcalf D. Effects of recombinant human granulocyte colonystimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72 : 2074-2081